Jennifer Taubert
2021
In 2021, Jennifer Taubert earned a total compensation of $10.2M as EVP, Worldwide Chair Pharmaceuticals at Johnson & Johnson, a 7% increase compared to previous year.
Compensation breakdown
| Change in Pension Value and Nonqualified Deferred Compensation Earnings | $1,067,411 |
|---|---|
| Non-Equity Incentive Plan | $1,510,314 |
| Option Awards | $1,713,005 |
| Salary | $938,077 |
| Stock Awards | $4,947,245 |
| Other | $49,707 |
| Total | $10,225,759 |
Taubert received $4.9M in stock awards, accounting for 48% of the total pay in 2021.
Taubert also received $1.1M of change in pension value and nonqualified deferred compensation earnings, $1.5M in non-equity incentive plan, $1.7M in option awards, $938.1K in salary and $49.7K in other compensation.
Rankings
In 2021, Jennifer Taubert's compensation ranked 1,007th out of 12,415 executives tracked by ExecPay. In other words, Taubert earned more than 91.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,007 out of 12,415 | 92nd |
Division Manufacturing | 337 out of 5,505 | 94th |
Major group Chemicals And Allied Products | 112 out of 2,375 | 95th |
Industry group Drugs | 95 out of 2,096 | 96th |
Industry Pharmaceutical Preparations | 63 out of 1,546 | 96th |
Source: SEC filing on March 16, 2022.
Taubert's colleagues
We found four more compensation records of executives who worked with Jennifer Taubert at Johnson & Johnson in 2021.